CRISPR

  • CRISPR pioneer Jennifer Doudna shines hope on the future of genetic modification at SXSW

    CRISPR pioneer Jennifer Doudna shines hope on the future of genetic modification at SXSW

    Jennifer Doudna, co-inventor of CRISPR Cas9 technology, or the ability to program genes using a special enzyme, spoke about the promises of this technology onstage at SXSW this afternoon. In a keynote today, Doudna noted that while this technology is very young (less than five years old), “it’s been deployed very rapidly for existing applications.” Read More

  • How Synthego’s founders went from a mission to Mars to a mission to cure disease Crunch Network

    How Synthego’s founders went from a mission to Mars to a mission to cure disease

    When an entrepreneur quits their job to found a company, you’re bound to hear the words “I want to build something meaningful. I want to have a bigger impact.” Well, if your job is building rockets for Elon at SpaceX, what do you say? What’s bigger than colonizing Mars? For the SpaceX engineers behind Synthego, the answer was helping cure all human disease. Read More

  • Bio
    CRISPR-Cas9 inventor Jennifer Doudna’s plans on moving forward, genetically modifying humans

    CRISPR-Cas9 inventor Jennifer Doudna’s plans on moving forward, genetically modifying humans

    The decision of who owned the rights to a hotly disputed CRISPR gene editing patent came down in favor of the Broad Institute of MIT and Harvard today so you’d think the mood would be sour at the University of California, Berkeley, the other contender in the case. But Berkeley’s Jennifer Doudna tells TechCrunch this is a positive for her. “I’m actually delighted to know… Read More

  • Judge rules CRISPR-Cas9 patents belong to Broad Institute of Harvard and MIT

    Judge rules CRISPR-Cas9 patents belong to Broad Institute of Harvard and MIT

    Following a high-profile and very heated court hearing over ownership of the patents for gene-editing technology CRISPR-Cas9, judges at the United States Patent and Trademark Office in Alexandria, Virginia, ruled today that the technology belongs to the Broad Institute of MIT and Harvard, not the University of California Berkeley, STAT News first reported. This is a big blow to UC Berkeley… Read More

  • Bio
    Move over Cas9, CRISPR-Cas3 might hold the key to solving the antibiotics crisis

    Move over Cas9, CRISPR-Cas3 might hold the key to solving the antibiotics crisis

    Researchers at North Carolina-based Locus Biosciences think they have a potential cure for antibiotic resistance using CRISPR’s lesser-known Cas3 enzyme. Most of the interest in CRISPR technology centers around the enzyme Cas9, which acts as a type of genetic scissors, allowing scientists to snip out, edit and replace DNA at certain intervals along the genome. However, Cas3 goes beyond… Read More

  • Weekly Roundup: Facebook’s fake news, MacBook Pro reviewed, first human CRISPR-ed

    Weekly Roundup: Facebook’s fake news, MacBook Pro reviewed, first human CRISPR-ed

    Facebook’s fake news frenzy continued as the company came under scrutiny for its debated influence on the U.S. election, LinkedIn was blocked in Russia and a human CRISPR-ed for the first time. Also, the human species has about 1,000 years left according to Stephen Hawking. But do we deserve survival? The existence of Coca-Cola’s selfie bottle points toward no. Read More

  • Bio
    Chinese scientists CRISPR a human for the first time

    Chinese scientists CRISPR a human for the first time

    A group of Chinese scientists injected a human being with cells genetically edited using CRISPR-Cas9 technology. This is the first time CRISPR has been used on a fully formed adult human and it’s encouraged a biomedical battle between China and the United States. The scientists from China are hoping the genetically edited cells will help their patient fend off a virulent type of… Read More

  • Bio
    Oral arguments for who owns CRISPR-Cas9 start next month

    Oral arguments for who owns CRISPR-Cas9 start next month

    The date has been set for oral arguments to begin over who owns the patent rights to the gene-editing wonder CRISPR-Cas9. Berkeley’s Jennifer Doudna and her colleague from the Max Planck Institute Emmanuelle Charpentier head to court on December 6th to face off against MIT’s Feng Zhang and present their argument before three US Patent and Trademark Office judges on why… Read More

  • This is the CRISPR-inspired bio-terror drama we deserve, but not the one we need

    This is the CRISPR-inspired bio-terror drama we deserve, but not the one we need

    CRISPR is like graphene. It’s one of those exciting new technologies science nerds will invariably invoke as a sort of game changer for every industry imaginable. And indeed, the gene-editing tool has already been unleashed on an impressive range of life-altering tasks, from the removal of malaria from mosquitos to a potential treatment for HIV. But there’s one job even those… Read More

  • Bio
    CRISPR loses Nobel to tiny machines

    CRISPR loses Nobel to tiny machines

    CRISPR, the gene-editing technology revolutionizing the biotech industry, has failed to take home the Nobel prize in chemistry for the second year in a row. Instead, the award went to Jean-Pierre Sauvage, J. Fraser Stoddart, and Bernard L. Feringa – three men who developed the world’s smallest machines using molecular physics. Each will share equally in the 8 million Swedish kronor… Read More